Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Given New $60.00 Price Target at Citigroup

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target increased by Citigroup from $50.00 to $60.00 in a research report released on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

KNSA has been the subject of a number of other research reports. Canaccord Genuity Group assumed coverage on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They issued a “buy” rating and a $62.00 price objective for the company. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a research note on Sunday. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research note on Friday, April 17th. Jefferies Financial Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Tuesday, April 21st. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.86.

Kiniksa Pharmaceuticals International Stock Down 1.6%

Shares of NASDAQ:KNSA opened at $52.99 on Wednesday. The company has a market capitalization of $4.06 billion, a price-to-earnings ratio of 71.61 and a beta of 0.06. Kiniksa Pharmaceuticals International has a 52 week low of $24.85 and a 52 week high of $54.31. The firm has a 50 day moving average of $46.26 and a 200 day moving average of $43.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. The company had revenue of $214.27 million during the quarter, compared to the consensus estimate of $207.12 million. Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. Kiniksa Pharmaceuticals International’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.11 earnings per share. On average, sell-side analysts expect that Kiniksa Pharmaceuticals International will post 1.09 EPS for the current year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, CEO Sanj K. Patel sold 7,278 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, April 6th. The shares were sold at an average price of $50.01, for a total value of $363,972.78. Following the transaction, the chief executive officer directly owned 7,278 shares of the company’s stock, valued at approximately $363,972.78. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ross Moat sold 2,367 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, April 6th. The stock was sold at an average price of $48.58, for a total transaction of $114,988.86. Following the completion of the transaction, the chief operating officer directly owned 12,029 shares in the company, valued at $584,368.82. This represents a 16.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 74,578 shares of company stock valued at $3,489,072. 53.48% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several institutional investors and hedge funds have recently bought and sold shares of KNSA. Rubric Capital Management LP grew its holdings in shares of Kiniksa Pharmaceuticals International by 2.3% during the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock valued at $155,320,000 after buying an additional 90,194 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Kiniksa Pharmaceuticals International by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock valued at $128,409,000 after buying an additional 49,802 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Kiniksa Pharmaceuticals International by 45.3% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock valued at $41,481,000 after buying an additional 332,846 shares during the last quarter. Qube Research & Technologies Ltd grew its holdings in shares of Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after buying an additional 653,236 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 8.7% during the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after buying an additional 67,452 shares during the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Q1 results beat expectations — Kiniksa reported $0.27 EPS vs. consensus $0.18 and revenue of $214.3M (up ~55.5% YoY), driven by ARCALYST product growth. Strong beat and high-margin progress support near-term earnings confidence. Press Release
• Positive Sentiment: FY‑2026 revenue guidance was raised to $930M–$945M vs. Street ~$912.7M — this upward guidance is a direct positive signal for revenue trajectory and model revisions. Guidance Release
• Positive Sentiment: Product momentum: ARCALYST net product revenue reported at $214.3M in Q1 and management increased 2026 ARCALYST expectations — supports revenue durability and valuation multiple expansion. Product Revenue Release
• Positive Sentiment: Pipeline catalysts: KPL‑387 Phase 2 recurrent pericarditis data expected in 2H‑2026 and a Phase 3 pivotal trial anticipated to start by year‑end — upcoming readouts could be meaningful share-price catalysts. Pipeline Release
• Positive Sentiment: Analyst upgrades and price‑target raises — multiple firms lifted targets (Jefferies to $71, Citigroup to $60, Canaccord to $64, Wedbush to $59, Wells Fargo to $57), reflecting higher revenue/earnings expectations and driving buy-side interest. Analyst Coverage More Analyst Notes
• Neutral Sentiment: Company materials and call: Q1 earnings slide deck and transcript are available for investors who want detail on channel dynamics, margins and guidance assumptions. Use these to validate the upbeat narrative. Earnings Presentation Call Transcript
• Negative Sentiment: Insider sale: Director Barry D. Quart sold 13,099 shares (~$50.10 avg) under a pre‑arranged Rule 10b5‑1 plan, reducing his stake ~51%. While pre‑planned, insider selling can still weigh on sentiment and may contribute to near‑term price pressure. SEC Filing Insider Trade Detail

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.